WIDER

Breast Cancer

A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer.

Key Team Members

Principal Investigator

Steven A. Madden, MD

Research Coordinator

Taylor Knight

Accepting Patients

Enrollment Started: March 24, 2026

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of the study is to evaluate the effects of the study drug ribociclib given in combination with standard endocrine therapy ET for participants diagnosed with early breast cancer. In particular, this study aims to assess if ribociclib in combination with adjuvant ET (study treatment) can help reduce the risk for breast cancer to come back.